About SCiStar Study

Clinical Research for Recent Spinal Cord Injury

SCiStar is a clinical research study evaluating the safety and activity of AST-OPC1 oligodendrocyte progenitor cells, an investigational agent for newly injured people with sensorimotor cervical (in the neck) spinal cord injury. This study has completed enrollment. The participants who have received AST-OPC1 will continue to be followed and Lineage Cell Therapeutics, Inc. will provide periodic study results updates at www.lineagecell.com. For the most up-to-date information and results, please view the SCiStar Study page at ClinicalTrials.com.

AST-OPC1 consists of neural cells known as oligodendrocyte progenitor cells, which are produced from human embryonic stem cells. AST-OPC1 was previously tested in the world’s first human clinical trial of a stem cell derived product.

Researchers will assess the impact of AST-OPC1 on hand and arm function as measured by the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI), the standard exam used to measure function in spinal cord injury patients.

About Clinical Research and Stem Cells

Clinical research studies look at new ways to prevent, detect or treat disease. People with illness or disease participate to help others and for the potential to gain access to the newest treatment and specialized care. Stem cells are unique in their ability to self-renew as well as transform into different cell types in the body. Doctors are conducting a diverse array of stem cell research studies, from basic biology to studies focused on nervous system disorders such as spinal cord injury and ALS. Visit International Collaboration on Repair Discoveries (ICORD) for more information.